Recent News

• 05.19.2025 - Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology
• 05.12.2025 - Oncocyte Reports Q1 2025 Results and Business Progress
• 05.07.2025 - Oncocyte to Release First Quarter 2025 Results on May 12, 2025
• 04.30.2025 - Oncocyte Provides Positive Update on Clinical Trial Progress
• 04.29.2025 - Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity
• 04.02.2025 - Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference

Recent Filings

• 05.14.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.14.2025 - ARS Annual Report to Security Holders
• 05.14.2025 - DEF 14A Other definitive proxy statements
• 05.12.2025 - 8-K Current report
• 05.12.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.09.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.17.2025 - 8-K Current report
• 04.08.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 04.07.2025 - EFFECT Notice of Effectiveness